Hepatocellular Carcinoma in a Patient with Chronic Lymphocytic Leukaemia Involving the Liver
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
Abstract
A relationship between hepatocellular carcinoma and chronic lymphocytic leukaemia has been reported. This is a case of a 75-year-old woman with stable chronic lymphocytic leukaemia, not on treatment with an increased activity of serum alkaline phosphatase and negative liver disease work up. A liver biopsy revealed leukaemic infiltration without evidence of cirrhosis or fatty liver. Four years later, she presented with a rapidly progressive liver mass which was diagnosed as hepatocellular carcinoma histologically.
References
1.
Kataoka T, Tsukamoto Y, Kanazawa N, Izumi T, Awata N, Nishizawa Y
. Concomitant hepatocellular carcinoma and non-Hodgkin's lymphoma in a patient with nodular regenerative hyperplasia. Pathol Int. 2006; 56(5):279-82.
DOI: 10.1111/j.1440-1827.2006.01956.x.
View
2.
Di Stasi M, Sbolli G, Fornari F, Cavanna L, Rossi S, Buscarini E
. Extrahepatic primary malignant neoplasms associated with hepatocellular carcinoma: high occurrence of B cell tumors. Oncology. 1994; 51(5):459-64.
DOI: 10.1159/000227383.
View
3.
Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D
. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006; 66(24):11851-8.
DOI: 10.1158/0008-5472.CAN-06-1377.
View
4.
Zauli G, Voltan R, Tisato V, Secchiero P
. State of the art of the therapeutic perspective of sorafenib against hematological malignancies. Curr Med Chem. 2012; 19(28):4875-84.
DOI: 10.2174/092986712803341548.
View
5.
Muzio M, Apollonio B, Scielzo C, Frenquelli M, Vandoni I, Boussiotis V
. Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy. Blood. 2008; 112(1):188-95.
DOI: 10.1182/blood-2007-09-111344.
View